New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
05:34 EDTNVS, CTICCell Therapeutics to reacquire rights to Pixuvri, Opaxio from Novartis
Cell Therapeutics (CTIC) announced that it has reached an agreement with Novartis (NVS) to reacquire rights to two anti-cancer compounds Pixuvri and Opaxio. Under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both compounds to date. Upon the effective date of termination, CTI will regain all rights that had been granted to Novartis. In exchange for Novartis' agreement to return such rights to CTI, CTI has agreed to make certain potential payments to Novartis based on sales of Opaxio and PIXUVRI and on any sublicense and certain other amounts payable to CTI.
News For CTIC;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
11:29 EDTNVSStudy says Valeant, others exploding dermatology drug prices, WSJ reports
The JAMA Dermatology journal published a new study that found that retail prices of 19 dermatologic prescription drugs increased fivefold on average between 2009 and 2015, reported The Wall Street Journal. Targretin, marketed by Valeant (VRX), jumped to $30,320 this year from $15,708 last year and $1,687 in 2009, the study found, but "It's not just Valeant," said lead author Miranda Rosenberg. Prices for drugs made by GlaxoSmithKline (GSK) and Novartis (NVS) at least doubled or tripled over the same time frame, the report noted. Reference Link
November 24, 2015
17:51 EDTNVSFDA approves first seasonal influenza vaccine containing an adjuvant
The U.S. FDA approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older. Fluad and Agriflu are manufactured by Novartis Vaccines and Diagnostics Limited, an affiliate of Novartis Vaccines and Diagnostics, based in Cambridge, Massachusetts. Reference Link
10:06 EDTNVSHigh option volume stocks
High option volume stocks: BDBD UNXL NVS SEDG BLOX GPRE SIG BPL TIF DY
05:32 EDTCTICCTI BioPharma announces advancement of tosedostat LI-1 trial
Subscribe for More Information
05:25 EDTNVSNovartis receives EU approval for Entresto
Novartis announced that the European Commission has approved Entresto for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction. Entresto is a twice a day tablet and has a unique mode of action which is thought to reduce the strain on the failing heart.
November 23, 2015
09:18 EDTCTICOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tyson Foods (TSN), up 2.4%... Mallinckrodt (MNK), up 7.4%. ALSO HIGHER: Novocure (NVCR), up 16.8% after announcing new Phase 3 data from Optune study... CTI BioPharma (CTIC), up 12.7% after the initiation of its rolling new drug application to the FDA for pacritinib... Peabody Energy (BTU), up 14.8% after announcing an asset sale... Sarepta Therapeutics (SRPT), up 5.2% following a positive mention in Barron's. DOWN AFTER EARNINGS: Trina Solar (TSL), down 5.6%. ALSO LOWER: Par Pacific (PARR), down 13.2% after pricing its 3.4M registered direct offering at $22.00... Lions Gate (LGF), down 2.9% after the "Hunger Games" finale opens below the series average.
05:39 EDTCTICCTI BioPharma initiates rolling submission of U.S. NDA for pacritinib
Subscribe for More Information
05:37 EDTNVSNovartis receives two EU approvals for Cosentyx
Novartis announced today that the European Commission has approved Cosentyx for the treatment of people living with ankylosing spondylitis, or AS, and psoriatic arthritis, or PsA. For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor, or anti-TNF, therapy. Cosentyx is the first in a new class of medicines called interleukin-17A, or IL-17A, inhibitors to be made available in Europe for AS and PsA. These approvals follow on from the earlier EC approval of Cosentyx for the first-line treatment of patients with moderate-to-severe plaque psoriasis. AS and PsA are common inflammatory joint conditions affecting approximately five million people in Europe, yet they remain significantly under-diagnosed and under-treated. If not treated effectively, they can lead to irreversible damage to the spine and joints, causing life-long pain and disability. New treatments are urgently needed for both conditions as many patients do not respond well to existing treatments, with up to 40% not responding sufficiently to anti-TNFs.
November 20, 2015
17:16 EDTNVSNovartis announces FDA approval of Tafinlar + Mekinist
Subscribe for More Information
14:41 EDTNVSNY AG leads team of states in $390M settlement with Novartis over kickbacks
Subscribe for More Information
14:00 EDTNVSNY AG leads team of states in $390M settlement with Novartis over kickbacks
Subscribe for More Information
10:52 EDTNVSFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTNVSIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
07:43 EDTNVSJefferies to hold a conference
Subscribe for More Information
November 17, 2015
16:38 EDTNVSAduro Biotech to delay filing 10-Q
Subscribe for More Information
07:34 EDTNVSOphthotech to hold a conference call
Subscribe for More Information
06:08 EDTNVSRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information
05:24 EDTNVSNovartis announces Phase III FLAME head-to-head trial met primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use